RxDoctor Payments Data

Jacob Feagans, MD

Gastroenterology · Santa Rosa Beach, FLNPI 1932389681

Payments from drug & device makers

$10,571in general payments, 2019–2025

Across 596 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$992
  • Pfizer$551
  • Takeda Pharmaceuticals U.S.A., Inc.$417
  • QOL Medical, LLC$396
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$10,36898%
  • Education$2042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,571 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$397,416
Medicare patients
856
Services billed
6,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid18$171,174
SucraidSacrosidase13$134,401
LinzessLinaclotide120$106,920
RinvoqUpadacitinib13$78,980
CreonLipase/Protease/Amylase34$57,188
XifaxanRifaximin16$47,378
ClenpiqSod Picosulf/Mag Ox/Citric Ac129$21,964
TrulancePlecanatide11$10,879
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates167$10,652
MovantikNaloxegol Oxalate22$8,819
VoqueznaVonoprazan Fumarate11$8,132
Budesonide DrBudesonide83$7,731
Budesonide EcBudesonide30$7,492
Mesalamine37$7,421
Dexlansoprazole DrDexlansoprazole21$6,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Rinvoq, Creon$3,488$243,089167 claims
Intercept Pharmaceuticals, Inc.Ocaliva$230$171,17418 claims
QOL Medical, LLCSucraid$396$134,40113 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$992$58,25827 claims
Ferring Pharmaceuticals Inc.Clenpiq$14$21,964129 claims
Redhill Biopharma Inc.Movantik$41$8,81922 claims
Phathom Pharmaceuticals, Inc.Voquezna$214$8,13211 claims
Braintree Laboratories, Inc.Sutab$174$1,93412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Santa Rosa Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →